Drug Profile
SAB 378
Latest Information Update: 09 Feb 2015
Price :
$50
*
At a glance
- Originator Novartis
- Class Analgesics
- Mechanism of Action Cannabinoid receptor CB1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain; Postherpetic neuralgia
Most Recent Events
- 22 Mar 2004 Phase-II clinical trials in Pain in USA (unspecified route)
- 22 Jan 2003 Phase-I clinical trials in Pain in USA (unspecified route)